A5071658743- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Nonmelanoma Skin Cancer Studies
- Eosinophilic Esophagitis
- Adenosine and Purinergic Signaling
- IL-33, ST2, and ILC Pathways
- Colorectal Cancer Treatments and Studies
- Polyomavirus and related diseases
- Immune Cell Function and Interaction
- Full-Duplex Wireless Communications
- Antenna Design and Analysis
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2020-2025
Abstract Background Immune checkpoint inhibitors (ICIs), such as anti-Cytotoxic T-Lymphocyte Antigen 4(CTLA-4) and anti-Programmed cell death protein 1 (PD-1) agents, have improved the prognosis of patients with metastatic melanoma. However, a proportion develop resistance to these treatments, leading poor prognosis. Therefore, identifying potential non invasive easy measure biomarkers is crucial for guiding treatment strategies in Methods A retrospective single-center study was conducted...
Abstract Background PD-1 blocking agents, such as nivolumab, have demonstrated clear anti-tumor effects and clinical benefits in a subset of patients with advanced malignancies. Nonetheless, more efforts are needed to identify reliable biomarkers for outcome, correctly select who will benefit from anti-PD-1 treatment. The aim this study was investigate the role peripheral CD8+T cells expressing CD73, involved generation immune suppressive molecule adenosine, predicting outcome after...
Abstract Background Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found affect immune populations which impact tumor development. The aim was investigate the prognostic significance IL-6 serum levels before and during treatment. Methods Serum were correlated with clinical outcomes in a retrospective study. Results Overall, 39 patients enrolled. High (> 5.6 pg/ml) associated poorer survival (45.1% vs...
Monoclonal antibodies targeting immune checkpoints improved clinical outcome of patients with malignant melanoma. However, the mechanisms are not fully elucidated. Since check-point receptors also expressed by helper innate lymphoid cells (ILCs), we investigated capability inhibitors to modulate ILCs in metastatic melanoma as well effects on ILC functions. Here, demonstrated that, compared healthy donors, showed a higher frequency total peripheral ILCs, lower percentages CD117+ ILC2s and...
The real-life application of immune checkpoint inhibitors (ICIs) may yield different outcomes compared to the benefit presented in clinical trials. For this reason, there is a need define group patients that from treatment. We retrospectively investigated 578 metastatic melanoma treated with ICIs at Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" Napoli, Italy (INT-NA). To compare patients' variables (i.e., age, lactate dehydrogenase (LDH), neutrophil-lymphocyte ratio (NLR),...
<h3>Background</h3> The immune checkpoint inhibitors (ICIs) revolutionized cancer therapeutic landscape and substantially improved the survival of patients (pts) with advanced malignancies, especially in skin pts.<sup>1–5</sup> IL-6 is a key inflammatory molecule secreted by M2 macrophages after polarization, mediating progression pancreatic colorectal cancer.<sup>6 7</sup> purpose this study to retrospectively investigate relationships between outcome treated immunotherapy. <h3>Methods</h3>...
<h3>Background</h3> The availability of immune checkpoint inhibitors (ICI) has radically changed the prognosis patients (pts) with metastatic melanoma. More recently, PD-1 have also become standard care as adjuvant therapy in high-risk and resected melanoma.<sup>1–7</sup> However, 65–80% treated ICI experience immune-related adverse events (irAEs)<sup>8</sup> causing morbidity a potential decrease clinical benefit. Currently, there are no biomarkers that can predict which at risk developing...
<h3>Background</h3> The immune checkpoint inhibitors revolutioned cancer therapeutic landscape and substantially improved the survival of patients with advanced malignancies, especially in skin patients.<sup>1–5</sup> Several predictive biomarkers are under evaluation, order to identify who can derive benefit from ICI while also limiting exposure toxicity. IL-6 is a pleiotropic cytokine involved not only responses but it major player chronic inflammatory diseases.<sup>6–7</sup> Additionally,...
Background Adjuvant treatment of melanoma patients with immune-checkpoint inhibition (ICI) significantly improved relapse-free survival (RFS). 1 In the phase 3 keynote-054 trial showed that pembrolizumab (anti-PD1) administration in adjuvant setting provided a longer RFS (59,8%) than placebo group (41,4%) at 3.5-year median follow-up. 2 Moreover, 4 years results from checkmate 238 trial, superior efficacy nivolumab versus ipilimumab resected AJCC-7 stage III or IV melanoma. rate was 58% arm...
<h3>Background</h3> Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer with neuroendocrine features, it associated elevated mortality. The pathogenesis presence of clonally integrated polyomavirus (MCPyV) or ultraviolet light (UV) exposure.<sup>1</sup> MCPyV causes up to 80% MCC tumors in North America Europe.<sup>2–4</sup> Recently immunotherapy having good results,<sup>5</sup> the phase 2 trial JAVELIN 200 indicated that treatment Avelumab (PDL1 inhibitor) patients metastatic...